2013
The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus
Look M, Saltzman WM, Craft J, Fahmy TM. The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials 2013, 35: 1089-1095. PMID: 24183697, PMCID: PMC4164020, DOI: 10.1016/j.biomaterials.2013.10.046.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCells, CulturedDendritic CellsDrug CarriersFemaleImmunosuppression TherapyImmunosuppressive AgentsLactic AcidLupus Erythematosus, SystemicMiceMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NZBMycophenolic AcidNanogelsPermeabilityPolyethylene GlycolsPolyethyleneiminePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerConceptsDendritic cellsTherapeutic immunosuppressionLupus-prone NZB/W F1 miceNZB/W F1 miceW F1 miceCell immunosuppressionImmunosuppressive therapyInflammatory cytokinesImmune modulatorsF1 miceImmune responseImmunosuppressionVivo efficacySurface markersMycophenolic acidGreater reductionParticulate uptakeAttractive modalityEfficacyCellsNanoparticulate platformSuccessful deliveryImmunosuppressantsLupusCytokinesNanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice
Look M, Stern E, Wang QA, DiPlacido LD, Kashgarian M, Craft J, Fahmy TM. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. Journal Of Clinical Investigation 2013, 123: 1741-1749. PMID: 23454752, PMCID: PMC3613921, DOI: 10.1172/jci65907.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusMedian survival timeMycophenolic acidLupus erythematosusImmune cellsLupus-prone NZB/W F1 miceNZB/W F1 miceSimilar therapeutic resultsW F1 miceSevere renal damageCD4 T cellsAntigen-presenting cellsLupus therapyRenal damageIL-12Immunosuppressant mycophenolic acidInflammatory cytokinesProphylactic useTherapeutic resultsF1 miceT cellsSurvival timeGreater dosesErythematosusImmunosuppression
2009
Lupus immunotherapy using CD4 targeted nanoparticles (48.29)
Look M, Stern E, Wang Q, DiPlacido L, Craft J, Fahmy T. Lupus immunotherapy using CD4 targeted nanoparticles (48.29). The Journal Of Immunology 2009, 182: 48.29-48.29. DOI: 10.4049/jimmunol.182.supp.48.29.Peer-Reviewed Original ResearchNZB/W F1 miceW F1 miceCD4 T cellsImmunosuppressive drugsDisease progressionF1 miceT cellsImmunosuppressive drug dosageSystemic lupus erythematosusNanoparticle therapyConventional therapeutic regimensFrequency of dosageLupus erythematosusAutoantibody productionTherapeutic regimensWeekly treatmentTherapeutic featuresAnimal modelsB cellsDrug dosageTherapeutic efficacyLupusImmunotherapyTherapyMice
1996
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Wang Y, Hu Q, Madri J, Rollins S, Chodera A, Matis L. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 8563-8568. PMID: 8710910, PMCID: PMC38712, DOI: 10.1073/pnas.93.16.8563.Peer-Reviewed Original ResearchConceptsNZB/W F1 miceNZB/WF1 miceLupus-like autoimmune diseaseW F1 miceF1 miceAutoimmune diseasesNew Zealand Black x New Zealand White F1 miceFemale NZB/W F1 miceFemale NZB/WF1 miceHuman systemic lupus erythematosusMonoclonal antibodiesCourse of glomerulonephritisSystemic lupus erythematosusImmune complex glomerulonephritisSystemic complement activationWhite F1 miceImmune complex nephritisMonths of ageSevere glomerulonephritisAntinuclear antibodiesComplement component C5Continuous therapyAutoimmune syndromeLupus erythematosusRenal disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply